Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. It also provides GMP flower sourcing, packaging, and distribution services for select international clients. In addition, it cultivates cannabis to sell as dried flower, pre-roll and other cannabis products for the adult use and medical markets. It also sells metered dose inhalers and aerosol sublingual sprays. Through Harvest Medicine, it provides clinic services to Canadian patients requiring medical cannabis education and prescriptions.


TSX:LABS - Post by User

Post by subaru1on May 15, 2024 2:38pm
129 Views
Post# 36041682

1Qrt results

1Qrt resultsCompare to 4qrt 2023.
Revenue increase $640K which is 6,5% not impressive
Gross/profit increase $55k which is 21 % good
Ebitda improve by $630k good.
The road for profatibility is there but speed limit is very low only 6,5% of revenue growth compare to qrt4 2023. Do a comparaison with qrt1 2023 is not good that qrt was a disaster not even 6 millions.
Personnaly i was expecting a much better qrt for the revenue and a Ebitda at 0 or very close.
They are expecting an improvement of 1 to 2 millions for the Ebitda in 2024 that's nice but the market wants more then that. It looks like we will be sitting around $0,08 for a while again, they could have give good guidance for 2qrt, no they are waiting after the US now, so the investors will have to wait after the US too i beleive. Does it worth to wait another 3 months for about the same results???? 
<< Previous
Bullboard Posts
Next >>